NVC-422
Phase 2Small molecule
NVC-422 is one of 17 small molecule programs targeting Viral Conjunctivitis. It is currently in Phase 2.
2
Indications
2
Total Trials
0
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
16 competitors in Impetigo
#DrugCompanyPhaseTrials
1Minocin
TTriax
Approved
Zyvox
PfizerPhase 3
Bactroban
PPadagis LLC
Phase 3
Fucidin
LEO PharmaApproved
Xepi
LLnhc
Phase 3
NVC-422
NNovaBay Pharmaceuticals, Inc.
Phase 2
Atx201
UUNION therapeutics
Phase 2
LTX-109
LLytix Biopharma AS
Phase 2
Topical Minocycline Foam FXFM244
VVyne Therapeutics Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NVC-422. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NNovaBay Pharmaceuticals, Inc.